{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:49:14Z","timestamp":1793627354526,"version":"4.5.1"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Patients with Myasthenia Gravis (MG) can be treated acutely with therapeutic plasma exchange (TPE) or intravenous immune globulin (IVIG). To date, there is no definitive understanding of which of the two treatments is more effective and safer. The purpose of this study was to systematically review the literature on the comparative efficacy and safety of TPE to other available treatments for MG.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A systematic literature search for studies published between 1997 and 2017 was performed per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using two database sources, MEDLINE (through the PubMed database) and Cochrane Library.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The search strategy resulted in 535 articles whose abstracts were reviewed. Among these, 165 full texts articles were reviewed for eligibility and 101 articles were excluded. Of the 165 articles, 64 articles were included for a systematic literature and 11 articles for a meta-analysis.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This systematic literature review and meta-analysis of treatment options showed that there was a higher response rate with TPE than IVIG in acute MG patients and patients undergoing thymectomy. There was no difference in mortality between the two treatment options. Our findings highlight the need for additional randomized clinical trials in these patients with MG.<\/jats:p>","DOI":"10.3389\/fneur.2021.662856","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:40:29Z","timestamp":1630708829000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence"],"prefix":"10.3389","volume":"12","author":[{"given":"Tina S.","family":"Ipe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeola R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S.","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","article-title":"Comparative analysis of therapeutic options used for myasthenia gravis","volume":"68","author":"Mandawat","year":"2010","journal-title":"Ann. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B3","unstructured":"Myasthenia gravis: practice essentials, background, anatomy\n            Abbas JowkarC\n            LorenzoN\n          Medscape2017"},{"key":"B4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun."},{"key":"B7","unstructured":"Myasthenia Gravis Fact Sheet2017"},{"key":"B8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis neuroanesthesia neurocritical care","volume":"1","author":"Linda","year":"2011","journal-title":"Case Stud"},{"key":"B9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","article-title":"A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients","volume":"117","author":"Alipour-Faz","year":"2017","journal-title":"Acta Neurol Belg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11748-005-1001-y","article-title":"Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis","volume":"53","author":"Nagayasu","year":"2005","journal-title":"Jpn J Thorac Cardiovasc Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity."},{"key":"B12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jneuroim.2010.09.015","article-title":"Plasma exchange and intravenous immunoglobulins: Mechanism of action in immune-mediated neuropathies","volume":"231","author":"Lehmann","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/NRL.0000000000000026","article-title":"IVIG versus PLEX in the treatment of worsening myasthenia gravis: What is the evidence? A critically appraised topic","volume":"19","author":"Dhawan","year":"2015","journal-title":"Neurologist."},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD002277","DOI":"10.1002\/14651858.CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2003","journal-title":"Cochrane Database Syst Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12028-009-9274-0","article-title":"Immunomodulatory therapies in neurologic critical care","volume":"12","author":"McDaneld","year":"2010","journal-title":"Neurocrit Care."},{"key":"B17","doi-asserted-by":"publisher","first-page":"CD002277","DOI":"10.1002\/14651858.CD002277.pub2","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous Immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/00062752-200311000-00005","article-title":"New directions in plasma exchange","volume":"10","author":"Winters","year":"2003","journal-title":"Curr Opin Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/14651858.CD002275","article-title":"Plasma exchange for generalised myasthenia gravis","volume":"4","author":"Gajdos","year":"2002","journal-title":"Cochrane Database Syst Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"CD002277","DOI":"10.1002\/14651858.CD002277.pub4","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1196\/annals.1405.001","article-title":"Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin","volume":"1132","author":"Gajdos","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"CD002277","DOI":"10.1002\/14651858.CD002277.pub3","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"1","author":"Gajdos","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/icvts\/ivt493","article-title":"Does repeat thymectomy improve symptoms in patients with refractory myasthenia gravis?","volume":"8","author":"Ng","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1136\/bmj.g7647","article-title":"PRISMA-P (preferred reporting items for systematic review and meta-analysis protocols) 2015 checklist : recommended items to address in a systematic review protocol","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ."},{"key":"B27","first-page":"231","article-title":"The treatment of severe forms of myasthenia gravis","volume":"13","author":"Iani","year":"1998","journal-title":"Funct Neurol."},{"key":"B28","first-page":"140","article-title":"Myasthenia gravis: how to treat?. Myopathies cardiomyopathies Off","volume":"23","author":"Tireli","year":"2004","journal-title":"J Mediterr Soc Myol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.33588\/rn.3305.2001132","article-title":"[A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia]","volume":"33","author":"P\u00e9rez Nellar","year":"2001","journal-title":"Rev Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials."},{"key":"B31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ."},{"key":"B32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","article-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders","volume":"13","author":"Skeie","year":"2006","journal-title":"Eur J Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jca.21470","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue","volume":"31","author":"Padmanabhan","year":"2016","journal-title":"J Clin Apheresis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Clin Apher."},{"key":"B35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jca.20129","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the apheresis applications committee of the American Society for Apheresis","volume":"22","author":"Szczepiorkowski","year":"2010","journal-title":"J Clin Apheresis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/jca.20129","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis","volume":"22","author":"Szczepiorkowski","year":"2007","journal-title":"J Clin Apher."},{"key":"B37","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update : plasmapheresis in neurologic disorders report of the therapeutics and technology assessment","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jama.256.10.1333","article-title":"NIH Consensus Development","volume":"256","year":"1986","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1055\/b-002-19458","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"Diener","year":"2008"},{"key":"B40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1567-5688(09)71827-6","article-title":"Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives","volume":"10","author":"Klingel","year":"2009","journal-title":"Atheroscler."},{"key":"B41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/ene.12703","article-title":"Myasthenia gravis: Descriptive analysis of life-threatening events in a recent nationwide registry","volume":"22","author":"Ramos-Fransi","year":"2015","journal-title":"Eur J Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve."},{"key":"B45","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"R\u00f8nager","year":"2001","journal-title":"Artif Organs."},{"key":"B46","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mus.23236","article-title":"Predictors of response to immunomodulation in patients with myasthenia gravis","volume":"45","author":"Katzberg","year":"2012","journal-title":"Muscle Nerve."},{"key":"B47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4103\/0028-3886.15050","article-title":"Myasthenic crisis: clinical features, complications and mortality","volume":"53","author":"Murthy","year":"2005","journal-title":"Neurol India."},{"key":"B48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/jnnp-2011-301449","article-title":"Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis","volume":"84","author":"Barnett","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/0300060516669893","article-title":"Predictors of extubation outcomes following myasthenic crisis","volume":"44","author":"Liu","year":"2016","journal-title":"J Int Med Res"},{"key":"B50","first-page":"478","article-title":"Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital","volume":"92","author":"Pittayanon","year":"2009","journal-title":"J Med Assoc Thail."},{"key":"B51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1756285616637046","article-title":"Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration","volume":"9","author":"Schneider-Gold","year":"2016","journal-title":"Ther Adv Neurol Disord."},{"key":"B52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"K\u00f6hler","year":"2011","journal-title":"J Clin Apher."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/00003246-199707000-00027","article-title":"Therapy of myasthenic crisis","volume":"25","author":"Berrouschot","year":"1997","journal-title":"Crit Care Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4103\/0972-2327.112466","article-title":"Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study","volume":"16","author":"Lal","year":"2013","journal-title":"Ann Indian Acad Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1510\/icvts.2007.170894","article-title":"Surgical outcome in thymic tumors with myasthenia gravis after plasmapheresis - a comparative study","volume":"7","author":"Sarkar","year":"2008","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"B56","doi-asserted-by":"publisher","first-page":"238783","DOI":"10.1155\/2013\/238783","article-title":"Preoperative plasmapheresis for elective thymectomy in myasthenia patient: is it necessary?","volume":"2013","author":"Saeteng","year":"2013","journal-title":"ISRN Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0022-5223(19)38763-X","article-title":"Effect of prethymectomy plasma exchange on postoperative respiratory function in myasthenia gravis","volume":"89","author":"d'Empaire","year":"1985","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B58","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/CND.0b013e3181660807","article-title":"Short report a comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis","volume":"9","author":"Jensen","year":"2008","journal-title":"J Clin Neuromuscul Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/thx.50.10.1080","article-title":"Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis","volume":"50","author":"Goti","year":"1995","journal-title":"Thorax."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"Eur J Neurol."},{"key":"B61","first-page":"939","article-title":"Long-term effects of plasma exchange in myasthenia. Results of a randomized study","volume":"12","author":"Gajdos","year":"1983","journal-title":"Presse Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/mus.23508","article-title":"A Retrospective study of complications of therapeutic plasma exchange in myasthenia","volume":"47","author":"Guptill","year":"2013","journal-title":"Muscle Nerve."},{"key":"B63","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/mus.21924","article-title":"Outcome of plasmapheresis in myasthenia gravis: Delayed therapy is not favorable","volume":"43","author":"Mandawat","year":"2011","journal-title":"Muscle Nerve."},{"key":"B64","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ejcts.2008.11.006","article-title":"Plasmapheresis before thymectomy in myasthenia gravis: routine versus selective protocols","volume":"35","author":"El-Bawab","year":"2009","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"B65","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00415-006-0235-7","article-title":"Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: A randomised trial","volume":"254","author":"Trikha","year":"2007","journal-title":"J Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/jnnp.44.6.469","article-title":"Plasma exchange and immunosuppressive drug treatment in myasthenia gravis : no evidence for synergy","volume":"1981","author":"Hawkey","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B67","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve."},{"key":"B68","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/jca.21454","article-title":"Report of the ASFA apheresis registry on muscle specific kinase antibody positive myasthenia gravis","volume":"32","author":"Yamada","year":"2017","journal-title":"J Clin Apher."},{"key":"B69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/(SICI)1098-1101(1997)12:4<165::AID-JCA2>3.0.CO;2-8","article-title":"Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange","volume":"12","author":"Rock","year":"1997","journal-title":"J Clin Apher."},{"key":"B70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jca.21346","article-title":"Citrate versus heparin for apheresis catheter locks: An efficacy analysis","volume":"30","author":"Passero","year":"2015","journal-title":"J Clin Apher."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00415-009-5091-9","article-title":"Risk factors for tumor occurrence in patients with myasthenia gravis","volume":"256","author":"Citterio","year":"2009","journal-title":"J Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mus.23626","article-title":"Safety of plasma exchange therapy in patients with myasthenia gravis","volume":"47","author":"Ebadi","year":"2013","journal-title":"Muscle Nerve."},{"key":"B73","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1525-139X.2011.01023.x","article-title":"Evidence-based review of therapeutic plasma exchange in neurological disorders","volume":"25","author":"Chhibber","year":"2012","journal-title":"Semin Dial."},{"key":"B74","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/mus.22080","article-title":"Practice parameters and focusing research: plasma exchange for myasthenia gravis","volume":"43","author":"Kaminski","year":"2011","journal-title":"Muscle Nerve."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CND.0000000000000119","article-title":"Human immunoglobulin versus plasmapheresis in guillain-barre syndrome and myasthenia gravis","volume":"18","author":"Ortiz Salas","year":"2016","journal-title":"J Clin Neuromuscul Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0955-3886(98)00022-8","article-title":"Plasmapheresis in myasthenia gravis. A survey","volume":"19","author":"Kuks","year":"1998","journal-title":"Transfus Sci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.662856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:40:36Z","timestamp":1630708836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.662856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":76,"alternative-id":["10.3389\/fneur.2021.662856"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.662856","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"article-number":"662856"}}